Literature DB >> 10820135

A distribution study with (14)C-otilonium bromide in the rat: evidence for selective tropism for large intestine after oral administration.

S Evangelista1, P Cochet, N Bromet, M Criscuoli, C A Maggi.   

Abstract

The aim of this study was to determine the plasma levels and the tissue distribution of otilonium bromide, measured as total radioactivity, after oral administration of 2 mg/kg of (14)C-labeled drug to rats. Radioactivity levels were very low in the plasma (ranging from 2.7 ng Eq/ml at 1.5 h to 0.6 ng Eq/ml at 24 h) as compared with those found in the gastrointestinal (GI) tract, indicating negligible systemic otilonium bromide absorption. Results from both quantitative radioluminography of whole body tissue distribution and radioassay of dissected parts of the GI tract carried out with liquid scintillation counting clearly demonstrate the presence of radioactive compounds in the walls of the GI tract at all sacrifice times. In the other tissues and organs examined, radioactivity was only found in trace amounts in the liver. The presence of radioactivity in the GI walls reflected the transit kinetics of drug-enriched contents. The radioactivity in large intestine walls was measurable at otilonium bromide concentrations in the range of micromole equivalents/kg, from 4 to 8 h after drug administration. Total body radioactivity recovery was 95, 101, 24, and 9% at 1.5, 4, 8, and 24 h, respectively. In conclusion, orally administered (14)C-otilonium bromide is poorly absorbed systemically, as indicated by the very low plasma radioactivity levels, but it is able to effectively penetrate into the large intestine walls, a recognized target for drugs oriented toward irritable bowel syndrome therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10820135

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  11 in total

1.  Changes in nitrergic and tachykininergic pathways in rat proximal colon in response to chronic treatment with otilonium bromide.

Authors:  G Cipriani; S J Gibbons; S A Saravanaperumal; J Malysz; L Sha; J H Szurszewski; D R Linden; S Evangelista; M S Faussone-Pellegrini; M G Vannucchi; G Farrugia
Journal:  Neurogastroenterol Motil       Date:  2015-04-30       Impact factor: 3.598

Review 2.  Irritable bowel syndrome.

Authors:  Antonella Spinelli
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

3.  T-type Ca(2+) channel modulation by otilonium bromide.

Authors:  Peter R Strege; Lei Sha; Arthur Beyder; Cheryl E Bernard; Edward Perez-Reyes; Stefano Evangelista; Simon J Gibbons; Joseph H Szurszewski; Gianrico Farrugia
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-03-04       Impact factor: 4.052

Review 4.  Colonic smooth muscle cells and colonic motility patterns as a target for irritable bowel syndrome therapy: mechanisms of action of otilonium bromide.

Authors:  Jakub Rychter; Francisco Espín; Diana Gallego; Patri Vergara; Marcel Jiménez; Pere Clavé
Journal:  Therap Adv Gastroenterol       Date:  2014-07       Impact factor: 4.409

Review 5.  Role of antispasmodics in the treatment of irritable bowel syndrome.

Authors:  Anita Annaházi; Richárd Róka; András Rosztóczy; Tibor Wittmann
Journal:  World J Gastroenterol       Date:  2014-05-28       Impact factor: 5.742

Review 6.  IBS and the role of otilonium bromide.

Authors:  Guy Boeckxstaens; Enrico S Corazziari; Fermín Mearin; Jan Tack
Journal:  Int J Colorectal Dis       Date:  2012-11-22       Impact factor: 2.571

7.  Inner and outer portions of colonic circular muscle: ultrastructural and immunohistochemical changes in rat chronically treated with otilonium bromide.

Authors:  Chiara Traini; Maria Simonetta Faussone-Pellegrini; Stefano Evangelista; Katia Mazzaferro; Gianluca Cipriani; Paolo Santicioli; Maria Giuliana Vannucchi
Journal:  PLoS One       Date:  2014-08-14       Impact factor: 3.240

8.  Efficacy of otilonium bromide in irritable bowel syndrome: a pooled analysis.

Authors:  Pere Clavé; Jan Tack
Journal:  Therap Adv Gastroenterol       Date:  2017-01-16       Impact factor: 4.409

Review 9.  Long-term efficacy and safety of otilonium bromide in the management of irritable bowel syndrome: a literature review.

Authors:  John K Triantafillidis; George Malgarinos
Journal:  Clin Exp Gastroenterol       Date:  2014-04-07

Review 10.  Pharmacologic Agents for Chronic Diarrhea.

Authors:  Kwang Jae Lee
Journal:  Intest Res       Date:  2015-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.